metsera glp-1 Metsera's Receptor Agonist MET-097i Pfizer M&A prospect Metsera heads

The ongoing debate: Controlled versus cured. While insurance companies may argue against continued coverage, the question is whether the patient is controlled by the medication rather than cured or in remission. Patients and their providers are often asked to submit letters of appeal to reverse insurance coverage denial decisions

The Price & Trust Transparency Score is designed to cut through the smoke and mirrors to show where a provider truly balances both

Furthermore, its short half-life of less than 3 h (Min et al., 2025) necessitates twice-daily injections to maintain efficacy, which can be a limiting factor for long-term patient adherence

From a practical point of view, different GLP-1RAs offer different dosing and device experiences, allowing practitioners to tailor treatment according to the needs of the individual patient